Cormedix INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

5 Mar 2026

CRMD

10-K: CorMedix Achieves Profitability, Expands Portfolio with Melinta Acquisition

CorMedix Inc. reported significant revenue growth and net income in 2025, driven by the successful commercialization of DefenCath and the strategic acquisition of Melinta Therapeutics, despite facing future reimbursement challenges.

NASDAQ

25 Mar 2025

CRMD

Cormedix INC

10-K: CorMedix Inc. Reports Profitable Year-End Following DefenCath Commercial Launch

CorMedix Inc. achieves profitability in the fourth quarter of 2024, driven by DefenCath sales, as detailed in its annual 10-K filing.

NASDAQ

12 Mar 2024

CRMD

Cormedix INC

10-K: CorMedix Inc. Announces Executive Separation and Files Annual Report

CorMedix Inc. details the separation agreement with its former General Counsel and provides an overview of its financial performance and business activities in its annual report.